Lynn E. S̄pitler

7.0k total citations
118 papers, 3.4k citations indexed

About

Lynn E. S̄pitler is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Lynn E. S̄pitler has authored 118 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Immunology, 51 papers in Oncology and 24 papers in Molecular Biology. Recurrent topics in Lynn E. S̄pitler's work include CAR-T cell therapy research (32 papers), Immunotherapy and Immune Responses (28 papers) and Monoclonal and Polyclonal Antibodies Research (20 papers). Lynn E. S̄pitler is often cited by papers focused on CAR-T cell therapy research (32 papers), Immunotherapy and Immune Responses (28 papers) and Monoclonal and Polyclonal Antibodies Research (20 papers). Lynn E. S̄pitler collaborates with scholars based in United States, United Kingdom and Canada. Lynn E. S̄pitler's co-authors include H. Hugh Fudenberg, Alan S. Levin, Joseph Wybran, Peter C. Dau, Christine K. Cassel, Edward E. Shev, Eric H. Denys, Jon Lindstrom, Antonino Catanzaro and Kenneth Μ. Moser and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

Lynn E. S̄pitler

116 papers receiving 3.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lynn E. S̄pitler United States 32 1.9k 1.1k 756 437 337 118 3.4k
E Platzer United States 26 2.0k 1.0× 1.6k 1.4× 817 1.1× 545 1.2× 955 2.8× 38 4.5k
Stephen A. Sherwin United States 29 1.2k 0.6× 1.0k 0.9× 793 1.0× 408 0.9× 347 1.0× 45 3.1k
Birger Christensson Sweden 42 2.1k 1.1× 1.6k 1.5× 1.3k 1.7× 567 1.3× 327 1.0× 160 5.8k
Giuseppe Tridente Italy 29 926 0.5× 413 0.4× 622 0.8× 353 0.8× 153 0.5× 129 2.6k
G A Currie United Kingdom 34 1.4k 0.7× 1.2k 1.1× 1.4k 1.8× 502 1.1× 489 1.5× 71 4.0k
Allan D. Hess United States 39 2.5k 1.3× 976 0.9× 1.3k 1.7× 427 1.0× 341 1.0× 156 5.1k
William R. Green United States 29 1.1k 0.6× 400 0.4× 683 0.9× 324 0.7× 254 0.8× 110 3.0k
Michael J. Brunda United States 29 3.1k 1.6× 1.6k 1.5× 1.0k 1.3× 1.2k 2.6× 737 2.2× 76 5.4k
Robert Peach United States 37 3.3k 1.7× 1.2k 1.1× 1.3k 1.7× 678 1.6× 528 1.6× 83 5.9k
Hideo Nariuchi Japan 35 2.8k 1.4× 633 0.6× 899 1.2× 384 0.9× 200 0.6× 130 4.3k

Countries citing papers authored by Lynn E. S̄pitler

Since Specialization
Citations

This map shows the geographic impact of Lynn E. S̄pitler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lynn E. S̄pitler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lynn E. S̄pitler more than expected).

Fields of papers citing papers by Lynn E. S̄pitler

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lynn E. S̄pitler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lynn E. S̄pitler. The network helps show where Lynn E. S̄pitler may publish in the future.

Co-authorship network of co-authors of Lynn E. S̄pitler

This figure shows the co-authorship network connecting the top 25 collaborators of Lynn E. S̄pitler. A scholar is included among the top collaborators of Lynn E. S̄pitler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lynn E. S̄pitler. Lynn E. S̄pitler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ott, Patrick A., Anna C. Pavlick, Douglas B. Johnson, et al.. (2016). A phase 2 study of glembatumumab vedotin (GV), an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma. Annals of Oncology. 27. vi393–vi393. 7 indexed citations
2.
Kaufman, Howard L., Robert Hans Ingemar Andtbacka, Frances A. Collichio, et al.. (2014). Primary overall survival (OS) from OPTiM, a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma.. Journal of Clinical Oncology. 32(15_suppl). 9008a–9008a. 36 indexed citations
3.
S̄pitler, Lynn E., Peter D. Boasberg, Omid Hamid, et al.. (2013). Phase II Study of Nab-Paclitaxel and Bevacizumab as First-line Therapy for Patients with Unresectable Stage III and IV Melanoma. American Journal of Clinical Oncology. 38(1). 61–67. 26 indexed citations
4.
S̄pitler, Lynn E., Robert Weber, Robert E. Allen, et al.. (2009). Recombinant Human Granulocyte-macrophage Colony-stimulating Factor (GM-CSF, Sargramostim) Administered for 3 Years as Adjuvant Therapy of Stages II(T4), III, and IV Melanoma. Journal of Immunotherapy. 32(6). 632–637. 46 indexed citations
5.
S̄pitler, Lynn E.. (2002). Noninterferon-based adjuvant therapy for high-risk melanoma. Expert Review of Anticancer Therapy. 2(5). 547–562. 2 indexed citations
6.
Retsas, Spyros, Carla I. Falkson, & Lynn E. S̄pitler. (2002). Report on the 4th International Conference on the Adjuvant Therapy of Malignant Melanoma held at the Royal College of Physicians, London, UK, 15–16 March 2002. Melanoma Research. 12(3). A1–A4. 2 indexed citations
7.
Meidenbauer, Norbert, David T. Harris, Lynn E. S̄pitler, & Theresa L. Whiteside. (2000). Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer. The Prostate. 43(2). 88–100. 97 indexed citations
8.
Muderhwa, J.M., Gary R. Matyas, Lynn E. S̄pitler, & Carl R. Alving. (1999). Oil-in-water liposomal emulsions: Characterization and potential use in vaccine delivery. Journal of Pharmaceutical Sciences. 88(12). 1332–1339. 29 indexed citations
9.
Kikuchi, Takao, et al.. (1992). Penetration of anti-melanoma immunotoxin into multicellular tumor spheroids and cell kill effects. Cancer Immunology Immunotherapy. 35(5). 302–306. 7 indexed citations
10.
González, René, P Salem, Paul A. Bunn, et al.. (1991). Single-dose murine monoclonal antibody ricin A chain immunotoxin in the treatment of metastatic melanoma: a phase I trial.. PubMed. 3(4). 192–6. 12 indexed citations
11.
S̄pitler, Lynn E.. (1991). A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma.. Journal of Clinical Oncology. 9(5). 736–740. 53 indexed citations
12.
S̄pitler, Lynn E., R P Mischak, & Patrick J. Scannon. (1989). Therapy of metastatic malignant melanoma using xomazyme® Mel, a murine monoclonal anti-melanoma ricin A chain immunotoxin. International Journal of Radiation Applications and Instrumentation Part B Nuclear Medicine and Biology. 16(6). 625–627. 8 indexed citations
13.
S̄pitler, Lynn E.. (1988). Clinical studies: Solid tumors. Cancer treatment and research. 37. 493–514. 11 indexed citations
14.
S̄pitler, Lynn E., et al.. (1987). Clinical trials of transfer factor in malignancy.. PubMed. 3(4). 549–64. 2 indexed citations
15.
S̄pitler, Lynn E.. (1979). TRANSFER FACTOR IN IMMUNODEFICIENCY DISEASES*. Annals of the New York Academy of Sciences. 332(1). 228–235. 3 indexed citations
16.
Catanzaro, Antonino, Lynn E. S̄pitler, & Kenneth Μ. Moser. (1975). Cellular immune response in coccidioidomycosis. Cellular Immunology. 15(2). 360–371. 61 indexed citations
17.
Levin, Alan S., Vera S. Byers, H. Hugh Fudenberg, et al.. (1975). IMMUNOLOGIC PARAMETERS BEFORE AND DURING IMMUNOTHERAPY WITH TUMOR-SPECIFIC TRANSFER FACTOR. 7 indexed citations
18.
S̄pitler, Lynn E., et al.. (1972). EXPERIMENTAL ALLERGIC ENCEPHALITIS. The Journal of Experimental Medicine. 136(1). 156–174. 71 indexed citations
19.
S̄pitler, Lynn E., E. Benjamini, Janis Dillaha Young, Harvey Kaplan, & H. Hugh Fudenberg. (1970). STUDIES ON THE IMMUNE RESPONSE TO A CHARACTERIZED ANTIGENIC DETERMINANT OF THE TOBACCO MOSAIC VIRUS PROTEIN. The Journal of Experimental Medicine. 131(1). 133–148. 66 indexed citations
20.
S̄pitler, Lynn E. & H. Sherwood Lawrence. (1969). Studies of Lymphocyte Culture: Products of Sensitive Lymphocyte-Antigen Interaction. The Journal of Immunology. 103(5). 1072–1077. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by E Platzer Breakdown of academic impact, for papers by Stephen A. Sherwin Breakdown of academic impact, for papers by Birger Christensson Breakdown of academic impact, for papers by Giuseppe Tridente Breakdown of academic impact, for papers by G A Currie Breakdown of academic impact, for papers by Allan D. Hess Breakdown of academic impact, for papers by William R. Green Breakdown of academic impact, for papers by Michael J. Brunda Breakdown of academic impact, for papers by Robert Peach Breakdown of academic impact, for papers by Hideo Nariuchi
Rankless by CCL
2026